CEA和CA125预测子宫内膜癌淋巴结转移模型的外部验证:一项多机构队列研究。

IF 2.2 4区 医学 Q3 ONCOLOGY
Cancer Biomarkers Pub Date : 2025-03-01 Epub Date: 2025-04-04 DOI:10.1177/18758592241306265
Hao Lin, Hung-Chun Fu, Szu-Yu Huang, Chen-Hsuan Wu, Szu-Wei Huang, Shao-Chi Wang, Yu-Che Ou
{"title":"CEA和CA125预测子宫内膜癌淋巴结转移模型的外部验证:一项多机构队列研究。","authors":"Hao Lin, Hung-Chun Fu, Szu-Yu Huang, Chen-Hsuan Wu, Szu-Wei Huang, Shao-Chi Wang, Yu-Che Ou","doi":"10.1177/18758592241306265","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundWe previously utilized pretreatment tumor markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (CA125) for predicting lymph node metastasis (LNM) in endometrioid endometrial cancer (EC).ObjectiveThe aim of this study was to externally validate a nomogram developed in our previous single-center retrospective study.MethodsA multi-center validation study was conducted to recruit endometrioid EC patients from four branches of Chang Gung Memorial Hospital between 2009 and 2021, with patients participating in the original research being excluded. The previously established nomogram was applied with optimal cut-off values for CEA 1.4 ng/ml and CA125 40 U/mL identified through receiver operating characteristic (ROC) curves. The concordance index (C-index) was calculated to assess discrimination, and comparative negative predictive value (NPV) and negative likelihood ratio (NLR) were determined. Decision curve analysis (DCA) was plotted to evaluate our predictive model's clinical utility and net benefit.ResultsOverall, 1271 patients were included in this external validation study. The results demonstrated a C-index of 0.727, indicating moderate discrimination ability of the nomogram in predicting LNM in this independent cohort. Comparative analysis of NPV 97.2% and NLR 0.36 revealed performance metrics consistent with the original study, reinforcing the nomogram's potential clinical utility in ruling out the possibility of LNM if both pretreatment CEA and CA125 were less than 1.4 ng/ml and 40 U/mL, respectively. The DCA indicated that the nomogram provided clinical utility.ConclusionThe reproducible performance metrics in the independent large sample cohort underscore the robustness and generalizability of utilizing CEA and CA125 as predictors of LNM in endometrioid EC, suggesting its potential as a simple tool for clinicians in preoperative decision-making regarding lymphadenectomy.</p>","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"42 3","pages":"18758592241306265"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"External validation of CEA and CA125 prediction model for lymph node metastasis in endometrial cancer: A multi-institute cohort study.\",\"authors\":\"Hao Lin, Hung-Chun Fu, Szu-Yu Huang, Chen-Hsuan Wu, Szu-Wei Huang, Shao-Chi Wang, Yu-Che Ou\",\"doi\":\"10.1177/18758592241306265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BackgroundWe previously utilized pretreatment tumor markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (CA125) for predicting lymph node metastasis (LNM) in endometrioid endometrial cancer (EC).ObjectiveThe aim of this study was to externally validate a nomogram developed in our previous single-center retrospective study.MethodsA multi-center validation study was conducted to recruit endometrioid EC patients from four branches of Chang Gung Memorial Hospital between 2009 and 2021, with patients participating in the original research being excluded. The previously established nomogram was applied with optimal cut-off values for CEA 1.4 ng/ml and CA125 40 U/mL identified through receiver operating characteristic (ROC) curves. The concordance index (C-index) was calculated to assess discrimination, and comparative negative predictive value (NPV) and negative likelihood ratio (NLR) were determined. Decision curve analysis (DCA) was plotted to evaluate our predictive model's clinical utility and net benefit.ResultsOverall, 1271 patients were included in this external validation study. The results demonstrated a C-index of 0.727, indicating moderate discrimination ability of the nomogram in predicting LNM in this independent cohort. Comparative analysis of NPV 97.2% and NLR 0.36 revealed performance metrics consistent with the original study, reinforcing the nomogram's potential clinical utility in ruling out the possibility of LNM if both pretreatment CEA and CA125 were less than 1.4 ng/ml and 40 U/mL, respectively. The DCA indicated that the nomogram provided clinical utility.ConclusionThe reproducible performance metrics in the independent large sample cohort underscore the robustness and generalizability of utilizing CEA and CA125 as predictors of LNM in endometrioid EC, suggesting its potential as a simple tool for clinicians in preoperative decision-making regarding lymphadenectomy.</p>\",\"PeriodicalId\":56320,\"journal\":{\"name\":\"Cancer Biomarkers\",\"volume\":\"42 3\",\"pages\":\"18758592241306265\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/18758592241306265\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/18758592241306265","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究背景:本研究利用前处理肿瘤标志物癌胚抗原(CEA)和癌抗原125 (CA125)预测子宫内膜样子宫内膜癌(EC)的淋巴结转移(LNM)。目的本研究的目的是从外部验证我们之前的单中心回顾性研究中开发的nomogram。方法采用多中心验证研究方法,从长庚纪念医院4家分院2009 - 2021年招募子宫内膜样EC患者,排除原研究患者。通过受试者工作特征(ROC)曲线确定CEA 1.4 ng/ml和CA125 40 U/ ml的最佳截止值。计算一致性指数(C-index)评价歧视,确定比较阴性预测值(NPV)和阴性似然比(NLR)。绘制决策曲线分析(DCA)来评估我们的预测模型的临床效用和净收益。结果总共有1271例患者被纳入该外部验证研究。结果显示,c指数为0.727,表明在该独立队列中,nomogram预测LNM的判别能力中等。NPV为97.2%,NLR为0.36,对比分析结果显示,如果预处理CEA和CA125分别低于1.4 ng/ml和40 U/ ml,则nomogram可以排除LNM的可能性。DCA显示nomogram临床应用价值。结论在独立的大样本队列中,可重复的性能指标强调了CEA和CA125作为子宫内膜样EC中LNM预测指标的稳健性和普遍性,表明其有潜力作为临床医生术前淋巴结切除术决策的简单工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
External validation of CEA and CA125 prediction model for lymph node metastasis in endometrial cancer: A multi-institute cohort study.

BackgroundWe previously utilized pretreatment tumor markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (CA125) for predicting lymph node metastasis (LNM) in endometrioid endometrial cancer (EC).ObjectiveThe aim of this study was to externally validate a nomogram developed in our previous single-center retrospective study.MethodsA multi-center validation study was conducted to recruit endometrioid EC patients from four branches of Chang Gung Memorial Hospital between 2009 and 2021, with patients participating in the original research being excluded. The previously established nomogram was applied with optimal cut-off values for CEA 1.4 ng/ml and CA125 40 U/mL identified through receiver operating characteristic (ROC) curves. The concordance index (C-index) was calculated to assess discrimination, and comparative negative predictive value (NPV) and negative likelihood ratio (NLR) were determined. Decision curve analysis (DCA) was plotted to evaluate our predictive model's clinical utility and net benefit.ResultsOverall, 1271 patients were included in this external validation study. The results demonstrated a C-index of 0.727, indicating moderate discrimination ability of the nomogram in predicting LNM in this independent cohort. Comparative analysis of NPV 97.2% and NLR 0.36 revealed performance metrics consistent with the original study, reinforcing the nomogram's potential clinical utility in ruling out the possibility of LNM if both pretreatment CEA and CA125 were less than 1.4 ng/ml and 40 U/mL, respectively. The DCA indicated that the nomogram provided clinical utility.ConclusionThe reproducible performance metrics in the independent large sample cohort underscore the robustness and generalizability of utilizing CEA and CA125 as predictors of LNM in endometrioid EC, suggesting its potential as a simple tool for clinicians in preoperative decision-making regarding lymphadenectomy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Biomarkers
Cancer Biomarkers ONCOLOGY-
CiteScore
5.20
自引率
3.20%
发文量
195
审稿时长
3 months
期刊介绍: Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信